Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.

Harbin, Laura M; Gallion, Holly H; Allison, Derek B; Kolesar, Jill M

Harbin, Laura M; Gallion, Holly H; Allison, Derek B; Kolesar, Jill M.

Afiliação

Harbin LM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, 800 Rose Street, Lexington, KY 40536-0596, USA.
Gallion HH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, 800 Rose Street, Lexington, KY 40536-0596, USA.
Allison DB; Department of Pathology & Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY 40536-0596, USA.
Kolesar JM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, 800 Rose Street, Lexington, KY 40536-0596, USA.

Diagnostics (Basel) ; 12(4)2022 Mar 29.

Article em En | MEDLINE | ID: mdl-35453890

Palavras-chave

NTRK inhibitors; PARP inhibitors; immunotherapy; next generation sequencing; ovarian cancer; precision medicine; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Diagnostics (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google